tg4-155 and Glioma

Population studies, preclinical, and clinical trials suggest a role for cyclooxygenase-2 (COX-2, PTGS2) in tumor formation and progression. The downstream prostanoid receptor signaling pathways involved in tumorigenesis are poorly understood, although prostaglandin E2 (PGE(2)), a major COX-2 metabolite which is usually upregulated in the involved tissues, presumably plays important roles in tumor biology. Taking advantage of our recently identified novel selective antagonist for the EP2 (PTGER2) subtype of PGE(2) receptor, we demonstrated that EP2 receptor activation could promote prostate cancer cell growth and invasion in vitro, accompanied by upregulation of the tumor-promoting inflammatory cytokines, such as IL-1β and IL-6. Our results suggest the involvement of prostaglandin receptor EP2 in cancer cell proliferation and invasion possibly via its inflammatory actions, and indicate that selective blockade of the PGE(2)-EP2 signaling pathway via small molecule antagonists might represent a novel therapy for tumorigenesis.

Topics: Animals; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cinnamates; Cytokines; Fluorescence Resonance Energy Transfer; Glioma; HEK293 Cells; Humans; Indoles; Male; Prostatic Neoplasms; Rats; Receptors, Prostaglandin E, EP2 Subtype; Regression Analysis; Transfection